Background
The ParSIFaL study is an open-label, randomized, controlled, multicenter phase II clinical trial. We recruit women with Er(+)/HEr2(-) La or MBc in first line therapy for advance disease (Table 1) . Participants are randomly assigned 1:1 using an interactive web-based randomization system, stratified by disease site and onset of metastatic disease diagnose to receive palbociclib plus fulvestrant (arm a) or palbociclib plus letrozole (arm B). Patients continue treatment until disease progression, symptomatic deterioration, unacceptable toxicity, death, or withdrawal of consent, whichever occurs first (Figure 1 ). Patients discontinuing the active treatment phase enter a treatment follow-up period during which survival and new anti-cancer therapy information is collected every 6 months from the last dose of investigational product. The treatment follow-up period continues up to 12 months after last included patient has been randomized into the study (Figure 2 ). The protocol approval was obtained at participating sites from institutional review board/independent ethics committee. Sites are located in 8 countries in Europe and middle East (Figure 3) . The primary endpoint is 1 year-progression free survival (1y-PFS) according to rEcIST (version 1.1). The primary efficacy analysis is to compare the efficacy of arm a against arm B. We assumed exponential survival functions. The analysis will be performed with two-sided Log-rank test. The investigator hypothesis (H1) is that 1y-PFS rate in arm a (85%) is higher than 1y-PFS rate in arm B (70%). We estimated a dropout rate of 15%. We plan one interim analysis after half of all expected patients have completed one year of follow-up or has been discontinued. The Haybittle-Peto significance level for testing the null-hypothesis within the interim and final analysis are 0.001 and 0.0495, respectively. The sample size is 304 patients. This design yield an overall type I error of 5% and a power of 85%. We will use cox proportional hazard models adjusting for stratified randomization variables. The main secondary endpoints are safety and tolerability related outcomes, time to progression, overall survival, overall response rate and clinical benefit. a series of prospective translational studies are planned in order to identify potential biomarkers and mechanism of resistance to palbociclib combined with endocrine therapy Palbociclib (P) is a cyclin dependent kinase inhibitor. In the phase II trial PaLoMa-1, the combination palbociclib (P) plus endocrine therapy was shown to be superior in terms of progression free survival (PFS) to endocrine therapy alone in endocrine receptor (Er)+/ HEr2(-), locally advanced (La) or metastatic breast cancer (MBc) patients. Based on the results of PaLoMa-1 trial, the P + Letrozole (L) combination received accelerated approval by Fda in 2015. Phase III trial comparing P+ fulvestrant (F) to F alone (PaLoMa-3 1 ) in hormonosensitive women who had progressed to a previous endocrine therapy showed improvement in PFS in the combination arm. accordingly, the Fda has expanded the indication for P, to be used in combination with F in these patients. In the phase II FIrST 
